Semi-closed Loop Automated Insulin Therapy in the Pediatric Population Aged 2-6 Years With Type 1 Diabetes: Impact on Quality of Life and Glycemic Control

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age2-6
SponsorFondation Lenval

About this trial

The incidence of type 1 diabetes is increasing, with an incidence of +4% per year in France today.

The treatment for type 1 diabetes is insulin therapy. In recent years, new systems have emerged, so-called "semi-closed loop" systems, also called automated insulin therapy, which have proven their superiority in terms of quality of life and glycemic balance in adults and children over 6 years old.

Since January 24, 2024, the HAS now recognizes the indication of the semi-closed loop for the YPSOPUMP model in children aged 2 to 6 years. This is the first reimbursement in France of a closed loop system for the 2-6 year old age group. There are currently few studies comparing the quality of life of children in semi-closed loop versus other treatments (open loop or injections). Regarding quality of life, the studies found mainly concern the contribution for parents and the improvement of adolescents' sleep as in the study by Erin C Cobry et al from 2020 (6).

Our study therefore aims to demonstrate an improvement in quality of life but also in diabetes balance in type 1 diabetic patients on a closed loop insulin pump versus open loop or injections in the pediatric population aged 2-6 years.

Eligibility criteria

Qualifiers

-Patients aged 2 to 6 years inclusive

Presenting type 1 diabetes on insulin therapy

Social security affiliates

Patient initiating semi-closed loop treatment

Disqualifiers

Opposition to participation in research involving humans or opposition to the use of data or samples and associated data (withdrawal of non-opposition).

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

20 Participants
are grouped into 1 trial group

Sponsors and collaborators